Literature DB >> 2981585

Cleavage of human von Willebrand factor by platelet calcium-activated protease.

T J Kunicki, R R Montgomery, J Schullek.   

Abstract

In human platelet lysates prepared by addition of nonionic detergent (Triton X-100) or by sonication, the multimer composition and electrophoretic mobility of platelet von Willebrand factor (vWF) were consistently modified under conditions that would favor activation of the endogenous calcium-activated, sulfhydryl-dependent neutral protease (CAP). By sodium dodecylsulfate-agarose gel electrophoresis, native platelet vWF contained some multimers that were larger than those characteristic of plasma vWF. Modified platelet vWF contained a multimer population equivalent to or smaller than that of plasma vWF plus an additional fast-migrating band. In crossed immunoelectrophoresis (CIE), modified platelet vWF was characterized by a more anodic distribution and the appearance of a distinct, cross-reactive, anodic component previously designated VIIIR:Ag fragment. In the presence of calcium, radiolabeled purified plasma vWF was also degraded by the protease in question, with a decrease in the apparent molecular weight of the reduced monomer from 230,000 to 205,000. The VIIR:Ag fragment isolated from the same degraded plasma vWF by preparative CIE was shown to be composed of an identical mol wt 205,000 subunit. Because cleavage of plasma or platelet vWF was inhibited by prior addition of leupeptin, EDTA, ethylene glycol bis (beta-aminoethyl ether)-N, N, N', N'-tetraacetic acid (EGTA), or N-ethylmaleimide (agents known to inhibit platelet CAP) but was unaffected by numerous other protease inhibitors, including soybean trypsin inhibitor, benzamidine, hirudin, phenylmethylsulfonyl fluoride, aprotonin, or epsilon-aminocaproic acid (none of which inhibits platelet CAP), we conclude that proteolysis of vWF observed in this study is a direct effect of CAP and is not mediated by way of secondary proteases.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981585

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

Review 1.  Calmodulin-binding proteins as calpain substrates.

Authors:  K K Wang; A Villalobo; B D Roufogalis
Journal:  Biochem J       Date:  1989-09-15       Impact factor: 3.857

2.  Calpain I remains intact and intracellular during platelet activation. Immunochemical measurements with monoclonal and polyclonal antibodies.

Authors:  J A Samis; G Zboril; J S Elce
Journal:  Biochem J       Date:  1987-09-01       Impact factor: 3.857

3.  High molecular weight kininogen is an inhibitor of platelet calpain.

Authors:  A H Schmaier; H Bradford; L D Silver; A Farber; C F Scott; D Schutsky; R W Colman
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

4.  Molecular basis of human von Willebrand disease: analysis of platelet von Willebrand factor mRNA.

Authors:  D Ginsburg; B A Konkle; J C Gill; R R Montgomery; P L Bockenstedt; T A Johnson; A Y Yang
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

5.  The effect of pathogen inactivation on cryoprecipitate: a functional and quantitative evaluation.

Authors:  Reed W Kamyszek; Matthew W Foster; Brooke A Evans; Keaton Stoner; Jessica Poisson; Amudan J Srinivasan; J Will Thompson; M Arthur Moseley; Micah J Mooberry; Ian J Welsby
Journal:  Blood Transfus       Date:  2020-08-06       Impact factor: 3.443

6.  Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor.

Authors:  J A Dent; S D Berkowitz; J Ware; C K Kasper; Z M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

7.  Proteolytic processing of von Willebrand factor subunit: heterogeneity in type-IIA von Willebrand disease.

Authors:  J Batlle; J Lasierra; A F Villamor; J L Navarro; A Pardo; M Campos; B Justiça; M F López Fernández
Journal:  Ann Hematol       Date:  1994-03       Impact factor: 3.673

8.  Substructure of human von Willebrand factor.

Authors:  W E Fowler; L J Fretto; K K Hamilton; H P Erickson; P A McKee
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

9.  Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE).

Authors:  T S Zimmerman; J A Dent; Z M Ruggeri; L H Nannini
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

10.  Characterization of proteoglycan degradation by calpain.

Authors:  K Suzuki; K Shimizu; T Hamamoto; Y Nakagawa; T Murachi; T Yamamuro
Journal:  Biochem J       Date:  1992-08-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.